Avidbiotics Corporation

Pylum Biosciences, Inc.

Dean M Scholl

Steven R Williams

Dana Gebhart

David W Martin, Jr

Gregory Govoni

Andrew Jamieson

Grace Lee

Urmi Chakraborty

David W Martin

Gregory R Govoni

Dana M Gebhart

Andrew C Jamieson

The present disclosure relates to the identification, cloning, and expression of a genetic locus within angenome that encodes a phage tail-like bacteriocin (PTLB), termed an enterocin. Also provided are non-natural enterocins, which have been engineered to have altered bactericidal specificity. Nucleic acid molecules encoding natural or non-natural enterocins, vector constructs containing such nucleic acids operably linked to a heterologous promoter, producer cells containing such vectors, the encoded enterocins, as well as methods of making and using such enterocins are described.

Enterocins and methods of using the same

The disclosure relates to the identification, cloning, and expression of a genetic locus within agenome that encodes a phage tail-like bacteriocin (PTLB), termed a monocin. Also provided are non-natural monocins, which have been engineered to have altered bactericidal specificity. Nucleic acid molecules encoding natural or non-natural monocins, vector constructs containing such nucleic acids operably linked to a heterologous promoter, producer cells containing such vectors, the encoded monocins, as well as methods of making and using such monocins are described.

Monocins and methods of use

This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically killbacteria, dangerous pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous aerobic producer cells. Disclosed also are small, non-ORF1374 receptor binding domains (RBDs), which are incorporated into diffocins to form engineered or variant diffocins having altered killing spectra. Variant diffocins provided herein may include a heterologous RBD and its cognate base plate attachment region (BPAR), or a fused BPAR. This invention offers a potent bactericidal agent with increased thermal and pH stability, and methods for producing it, in order to kill selectivelybacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.

Diffocins and methods of use thereof

This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically killbacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike, do not die in the presence of oxygen. Disclosed also is the specific gene of the isolated gene cluster that determines the killing spectrum of the R-type bacteriocin and the demonstration that the killing spectra of diffocins can be altered by engineering orf1374 of the diffocin genetic locus. This invention offers a potent bactericidal agent and a means to make it in order to kill selectivelybacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.

Diffocin and methods of use thereof

Recombinant P4 bacteriophage containing modified tail fibers having a base plate attachment region (BPAR) from a P2 bacteriophage gene H product and a heterologous receptor binding domain (RBD) are disclosed. Methods for the use of the recombinant P4 bacteriophage, such as to detect the presence of a target bacterium in a sample, are also described.

Recombinant bacteriophage and methods for their use

Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of, are disclosed as are methods for producing them in GRAS organisms. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.

Modified bacteriocins and methods for their use

Modified forms of naturally occurring bacteriocins, such as the R-type pyocins of, are disclosed. The bacteriocins are modified at the ends of their tail fibers in a region responsible for binding specificity and affinity to their cognate binding partners, or receptors, such as those on the surface of bacteria. Methods for the use of the modified bacteriocins, such as to bind receptors, including virulence or fitness factors, on the surfaces of bacteria, are also described.

Growing community of inventors

South San Francisco, CA, United States of America

Dean M Scholl